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Temozolomide is an alkylating cytostatic drug that finds increasing application in the treatment of melanoma, anaplastic astrocytoma
and glioblastoma multiforme. The compound is a prodrug that decomposes spontaneously, independent of an enzymatic activation
step. DNA methylation induces futile mismatch repair cycles and depletion of the DNA repair enzyme O
6-methylguanine-DNA
methyltransferase should then initiate programmed cell death. We show drug-dependent inhibition of tumour growth in a three-
dimensional cell culture model of the glioma cell lines U87MG and GaMG. Migrational behaviour of the glioblastoma cells remained
unaltered. However, coincubation of tumour spheroids with primary brain aggregates showed reduced tumour cell invasion into
brain tissue in the presence of temozolomide. This was not achieved by slowing cellular migration, as temozolomide-treated cells
displayed no reduced motility. By transferase-mediated dUTP nick-end labelling (TUNEL) of apoptotic nuclei, we found that the drug
was able to induce apoptosis throughout the tumour cell spheroids. Apoptosis was highest in the core region of the spheroids.
Repetitive application of sublethal doses of temozolomide to multicellular spheroids resulted in the development of drug resistance in
GaMG cells. We suggest that temozolomide is a strong initiator of apoptosis in glioblastoma tumour cells in a spheroid cell culture
system, when cells are already in a stressful environment.
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Patients with high-grade glioma have a poor prognosis. Surgical
removal of the tumour constitutes a first-line therapy. Unfortu-
nately, glioblastoma tumour cells are highly mobile and infiltrate
the surrounding, otherwise healthy, brain tissue. For this reason,
surgery has to be followed by radiation and in most of the cases by
chemotherapy to further lower the number of remaining tumour
cells. Most chemotherapeutic agents tested to date show only
marginal, if any, clinical benefit. Temozolomide is a recent
addition to the chemotherapeutic arsenal, and phase III clinical
trials for temozolomide treatment of recurrent high-grade
glioblastomas have shown responses to the drug, reflected in an
increased progression-free survival (Bower et al, 1997; Paulsen
et al, 1999; Janinis et al, 2000; Yung et al, 2000)
The alkylating agent temozolomide is a second-generation
imidazotetrazine prodrug. It can be administered orally and has
a bioavailability of almost 100%. The compound spontaneously
hydrolyses at physiological pH into the active degradation product
5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) (Tsang
et al, 1991; Denny et al, 1994). MTIC methylates DNA at
nucleophilic centres like N
7-GbN
3-A4N
1-A¼N
3-G¼O
6-G to
give an order of reactivity (Friedberg, 1985). The O
6-G-alkylation
is reversed by the O
6-methylguanine-DNA methyltransferase
(MGMT) in a reaction that leads to irreversible inactivation of
the enzyme protein. As MGMT is consumed by the demethylation
reaction, temozolomide is thought to deplete its own detoxification
mechanism. Furthermore, cotreatment of tumours with O
6-
benzylguanine, another otherwise nontoxic inhibitor of MGMT,
increases the sensitivity of MGMT positive cells towards temozo-
lomide (Dolan et al, 1990; Tentori et al, 1997).
In cells deficient in MGMT, O
6-methylguanine is not repaired
and results in the incorporation of a thymine (T) residue in the
complementary position at the next replication cycle. Tumour cells
that possess a functional postreplicative DNA mismatch-repair
(MMR) system remove the T residue, but then reinsert again a T
residue. In treated lymphoblastoid cells, several futile repair cycles
are then thought to accumulate p53 protein (D’Atri et al, 1998;
Tentori et al, 1998). An identical mechanism is also assumed for
glioma cells (Hirose et al, 2001). As a consequence of this, efficient
treatment of tumour cells requires, first, a functional postreplica-
tive MMR system and, second, a functional p53 protein. Cells
deficient in one of these components should show decreased
sensitivity against alkylating drugs and will continue to divide until
the occurrence of mitotic catastrophe. We have chosen two glioma
cell lines to study the effects of temozolomide on glioma spheroid
cultures. The U87MG cell line contains a functional p53 protein
and was described to be sensitive to cytostatic drugs (Li et al,
1997), while the GaMG cell line was described to be relatively
resistant to these compounds (Terzis et al, 1997).
Most of the studies on temozolomide and its activity against
glioma cells were carried out in monolayer cultures (Sankar et al,
1999; Hirose et al, 2001). The spheroid model is a three-
dimensional cell culture system that more closely resembles the
in vivo situation inside a tumour. Along the axis of spheroids,
steep gradients can exist for cellular oxygen levels, glucose
concentration, nutrients, serum-derived growth factors and pH
(Mueller-Klieser, 1987). Individual tumour cells growing under
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sthese conditions face a different environmental situation depend-
ing on their position inside the three-dimensional framework of
the spheroid.
Moreover, the coculture model of foetal brain-derived brain
aggregates and glioma spheroids offers a permissive substrate to
investigate glioma cell invasion. We applied this model to
investigate the effects of temozolomide on invasion.
It was our aim to study the effects of temozolomide on tumour
cell migration, proliferation and invasion in a well-defined three-
dimensional spheroid culture system. In addition, we asked
whether glioblastoma cells grown as spheroids are able to undergo
temozolomide-induced apoptosis or employ mechanisms of
survival and resistance.
MATERIALS AND METHODS
Chemicals and drugs
Temozolomide was obtained from Essex Pharma (Munich,
Germany). The drug was added to the culture medium and diluted
serially prior to application. The human U87 cell line was obtained
from Dr J Ponte ´n, University of Uppsala, Sweden. The GaMG cell
line was kindly supplied by Dr R Bjerkvig, University of Bergen,
Norway (Akslen et al, 1988). Both cell lines were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% heat-inactivated newborn calf serum, 2% L-glutamine, 3.2%
nonessential amino acids (alanine, asparagine, aspartic acid,
glutamic acid, glycine, proline, serine), penicillin (100IUml
 1)
and streptomycin (100mgml
 1) and kept in standard tissue culture
conditions.
Proliferation assay
Multicellular spheroids were aggregated from single-cell suspen-
sion and grown for 7–10 days in liquid overlay culture. Equally
sized spheroids with diameters of about 250mm were placed in 24-
well culture dishes (NUNC, Roskilde, Denmark) base-coated with
0.8% agar. Spheroidal volume growth was monitored daily and
spheroid volume was calculated using the equation
4=3pððD1 þ D2Þ=4Þ
3;
where D1 and D2 are the maximal diameters of the spheroids
measured in rectangular directions.
Temozolomide was applied in a single dose in concentrations
ranging from 0.1 to 20mgml
 1 (0.5mM–100mM) to eight individual
spheroids per temozolomide concentration. The drug was not
removed after application as the half-life of temozolomide and the
first derivative MTIC is about 2h (Kim et al, 1997).
Drug resistance because of dealkylating MGMT enzymatic
activity was probed by coincubating spheroids in 0.1 and 5mgl
 1
temozolomide in combination with 1 and 5mM O
6-benzylguanine,
or with O
6-benzylguanine alone.
To study the spheroidal response to a repetitive treatment with
temozolomide, spheroids were treated with 10 or 20mgml
 1
temozolomide and incubated for 14 days. Thereafter, equally sized
spheroids were removed and again exposed to various drug
concentrations ranging from 0.1 to 20mgml
 1. Three independent
experiments were carried out.
Cellular migration
After 7 days of stationary culture in agar base-coated dishes,
individual multicellular spheroids were placed in 24-well culture
dishes. Upon adherence to the solid support, spheroids disas-
sembled and released cells migrated away radially from their initial
position. The area covered by cells was measured every 24h over a
period of 4 days. The area covered by the cells was taken as an
indicator of cellular migration ability. Eight glioma spheroids were
exposed to each temozolomide concentration in three independent
experiments.
Spheroid confrontation studies
Foetal brain aggregates of rat foetuses at embryonal day 18 were
prepared as described by Bjerkvig et al. (1986). Briefly, brains were
removed, minced with scalpel blades and serially treated with
diluted trypsin solution. Brain aggregates formed in agar base-
coated 24-well dishes and were matured over 3 weeks. Equally
sized brain aggregates and glioblastoma cell spheroids were
juxtaposed in agar base-coated 96-well culture dishes. Temozolo-
mide was added after the two spheroids adhered. Confrontation
cocultures were documented daily on an inverse photomicroscope.
Four independent experiments with six confrontations per
temozolomide concentration were carried out.
TUNEL assay
Dewaxed sections of temozolomide-treated spheroids were boiled
briefly in 10mM citrate buffer, pH 6.0. After blocking nonspecific
labelling with PBS containing 2% BSA, 0.5% NP40, sections were
incubated in a terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labelling (TUNEL) reaction solution containing
9m M dUTP, 1mM DIG-labelled dUTP (Roche, Mannheim Ger-
many), 2.5mM cobalt chloride, 100mM Tris pH 7.6 and 0.3Uml
 1
terminal deoxynucleotidyl transferase. After 1h at 371Ci na
humidified atmosphere, the sections were washed twice in PBS,
incubated with an anti-DIG-horseradish peroxidase conjugate in a
1:200 dilution (Roche, Mannheim, Germany). Unbound anti-DIG-
horseradish peroxidase conjugate was removed by extensive
washes. TUNEL positive nuclei were visualised by nickel-enhanced
diaminobenzidine staining. Three independent experiments were
carried out. Five slides of each 20mgml
 1 and untreated control
sections were stained. Positively staining nuclei of 50 spheroidal
sections per condition were counted and related to the total
number of nuclei.
DNA fragmentation
Multicellular spheroids were harvested 2 and 7 days after drug
treatment. Spheroids were homogenised by five freeze–thaw
cycles. Nuclei were collected by centrifugation at 1000g for
10min. Supernatant was removed and protein content was
quantified by bicinchoinic-acid assay (Pierce). Nuclei were
incubated in 70% ethanol at  201C overnight. Low molecular
weight DNA was extracted according to the method described by
Gong (Gong et al, 1994). Briefly, nuclei were centrifuged at 800g
for 5min, the ethanol was removed and nuclei were resuspended in
200ml 0.1 M sodium phosphate, 0.1 M sodium citrate buffer, pH 7.4
0.02% NP40, and 75mgml
 1 RNAse A was added and incubated for
1h. 150U proteinase K was added and incubated for 2h. Fractions
of the solution normalised to the protein content of the
supernatant were loaded on a 1.5% TAE-agarose gel, run at
0.5Vcm
 1 for 5h, stained by ethidium bromide and documented.
Senescence detection
Senescent cells were identified according to the method described
by Dimri et al. (1995). Briefly, temozolomide-treated spheroids
were washed twice in PBS, fixed in 2% paraformaldehyde, 0.2%
glutardialdehyde in PBS for 5min, washed again in PBS and
incubated overnight at 371C in a staining solution containing
1mgml
 1 X-Gal, 20mM potassium ferricyanide, 20mM potassium
ferrocyanide, and 2mM MgCl2 in 40mM citric acid/sodium
phosphate buffer at pH 6.0. Subsequently, spheroids were washed,
dehydrated and paraffin embedded, sectioned and counterstained
Temozolomide and apoptosis in glioblastoma spheroids
WG u ¨nther et al
464
British Journal of Cancer (2003) 88(3), 463–469 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
swith nuclear fast red and documented using a Leica Aristoplan
microscope.
RESULTS
Proliferation and migrational characteristics
Spheroids derived from the two glioblastoma cell lines U87MG and
GaMG were exposed to increasing concentrations of temozolomide
and showed a concentration-dependent relative growth inhibition
(Figure 1A, B). Growth kinetics of spheroids from both cell lines
displayed an exponential growth phase. GaMG spheroids grew
faster than U87MG and reached a plateau phase of growth after 16
days of culture. At this time point, U87 spheroids were still
growing exponentially. While GaMG spheroids were more resistant
to the cytotoxic effects of temozolomide, U87MG-derived spher-
oids displayed an increased sensitivity towards temozolomide. As
expected, the migrational behaviour of both glioblastoma cell lines
was unaffected by temozolomide (Figure 1C, D). As shown by the
radial migration assay, tumour cells from a disassembling spheroid
did not show a concentration-dependent inhibition of locomotor
characteristics. Only prolonged incubation with temozolomide
resulted in reduced radial migration, presumably because of
general reduction of cell number related to the antiproliferative
action of temozolomide.
Tumour cell invasion
In cocultures between GaMG and U87MG spheroids, and mature
foetal rat brain aggregates, a marked replacement of brain tissue by
invading glioma cells was observed (Figure 2). In the confrontation
zone, the outer fibrous layer of glial cells was lost and the brain
aggregate volume was noticeably reduced. The tumour spheroids
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Figure 1 Volume growth of (A) GaMG and (B) U87MG spheroids. Spheroids treated with temozolomide show a concentration-dependent inhibition of
volume growth. Error bar¼s.e.m. (C, D) Radial migration of tumour cells. Area covered by cells migrating away radially from disassembling (C) GaMG
spheroids and (D) U87 spheroids after placement on an uncoated cell culture dish. No difference in migration ability was observed between treated and
control cells. After 5 days, differences of proliferative activity add to the migrational behaviour. Error bar¼s.d.
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swere treated with temozolomide 3 days before confronting them to
brain aggregates. As shown in Figure 1A and B, this period was
long enough to induce growth inhibition. Treated tumour
spheroids showed a reduction in the invasion velocity, but no
change of invasion pattern was observed (Figure 2A–F).
Acquired resistance after repetitive temozolomide
administration
To mimic the repetitive application of temozolomide in clinical
treatment, we applied temozolomide twice in 14-day intervals. It
was our intention to get an estimate of the tumour cells’ ability to
develop resistance mechanisms against temozolomide. In the first
round of treatment, U87 and GaMG spheroids were exposed to
either 10 or 20mgml
 1 temozolomide. In the second round of
treatment, 14 days after the first application, temozolomide in
concentrations ranging from 0.1 to 20mgml
 1 was applied and
volume growth was compared to untreated, equally sized control
spheroids. While U87 MG spheroids did not survive a second
application, GaMG spheroids displayed an increased resistance to
temozolomide irrespective of whether the initial treatment was at
10 or 20mgml
 1 temozolomide. The IC50 values for GaMg at day 8
after the second treatment with temozolomide were above
20mgml
 1 (Table 1). Control spheroids at this time point gave
an IC50 value of 9.871.3mgml
 1. Upon extended incubation, 13
days after the second treatment, an IC50 could not be reached
anymore. An IC30 of 5.771.9mgml
 1 for control GaMg spheroids,
13mgml
 1 for 10mgml
 1 pretreated GaMG spheroids and
13mgml
 1 for 20mgml
 1 pretreated GaMG spheroids was
determined. In general, repetitive drug application leads to
spheroid volume growth reduction and to a fast development of
drug resistance.
TUNEL in sections of spheroids
Apoptosis as a result of cytostatic drug application was seen in
both cell lines employed. Labelling of degraded DNA in apoptotic
nuclei gives an estimate of the cytotoxic action of the drug.
Distribution of apoptotic nuclei in multicellular spheroids of both
cell lines showed a tendency towards an accumulation of apoptotic
cells in the central region of the spheroids. To distinguish between
apoptosis and necrosis, untreated control spheroids with similar
diameters as the treated spheroids were also stained by the TUNEL
assay. These control spheroids neither showed a central necrosis
nor a significant number of TUNEL positive nuclei (Figure 3A, C).
The GaMG cell line showed only a slight induction of apoptosis as
indicated in Figure 3D, while the U87 cell line was strongly driven
into the programmed cell death with a high percentage of
apoptotic nuclei per section (Figure 3B). After 2 days, the
percentage of TUNEL positive cells was 10.772.4% for the U87
spheroids treated with 20mgml
 1 temozolomide, but almost no
apoptotic nuclei were found in untreated U87 spheroids
(Figure 3C). The 20mgml
 1 temozolomide-treated GaMG spher-
oids contained 2.370.3% TUNEL positive nuclei, while the
respective control spheroids were almost without TUNEL positive
nuclei; Po0.01, t-test, relative number of TUNEL positive nuclei
compared to untreated control.
DNA fragmentation after temozolomide treatment
To confirm that positive staining of cell nuclei in treated spheroids
was because of apoptosis and not to necrosis, we performed a DNA
fragmentation analysis. We observed a strong induction of the
typical DNA degradation pattern as a result of apoptosis in U87
1 h  24 h 48 h 
1 h  24 h 48 h
T  B 
control 
20 g ml-1   U87 MG 
U87 MG 
A BC
DEF
Figure 2 Invasion into foetal brain aggregates. Confrontation of U87MG
spheroids (T) with a 21-day-old foetal rat brain aggregate (B). (A–C)
Volume growth of the tumour spheroids is noticeably reduced at
20mgml
 1 temozolomide concentration compared to untreated controls
(D–F). As a consequence of this, reduced invasion capacity is observed.
Table 1 Repetitive treatment of multicellular glioblastoma spheroids
with temozolomide
Second treatment
First treatment
IC50 after
8 days
IC50 after
13 days
IC30 after
13 days
Untreated 9.871.3mgml
 1 14.071.6mgml
 1 5.771.9mgml
 1
10mgml
 1 temozolomide Not reached Not reached 13mgml
 1
20mgml
 1 temozolomide Not reached Not reached 13mgml
 1
IC50 and IC30 values were calculated by the relation of spheroid volume growth
between treated and untreated spheroids after the second treatment with
temozolomide
U87MG                                          U87MG 
GaMG                                             GaMG 
AB
CD
Control 20 g ml-1 
Control 20 g ml-1 
Figure 3 TUNEL labelling. Cross-sections of paraffin-embedded
spheroids, stained for fragmented DNA by TUNEL. The more loosely
associated U87 spheroids contain significantly more apoptotic nuclei 2 days
after temozolomide treatment (A, B). It takes about 6 days until there is a
significant number of apoptotic nuclei labelled in GaMG spheroids (C, D).
Nuclei are counterstained with nuclear fast red.
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sspheroids (Figure 4). At 2 days after treatment, a drug-dependent
induction of apoptosis was observed. GaMG spheroids at this time
point showed no laddering phenomenon. At a later stage, 7 days
after treatment, apoptosis in U87 spheroids was also prominent
in untreated control spheroids. A further increase in DNA
fragmentation could still be observed in temozolomide-treated
U87 spheroids. GaMG spheroids did not show a significant
DNA laddering phenomenon. Only spheroids treated with
5mgml
 1 exhibited a slight signal 7 days after treatment. These
findings correspond well with the results obtained in the TUNEL
assay.
Senescence
Cellular senescence is characterised by accumulation of lysosomal
enzymes. An intense staining because of lysosomal galactosidase
activity in spheroids derived from U87 cells was found. The
punctuate label, because of staining of lysosomal vesicles (Kurz
et al, 2000), was observed only after the application of
temozolomide. In contrast to this, the GaMG cell line did not
show any galactosidase positive intracellular vesicles. In this case,
temozolomide did not induce an accumulation of galactosidase
positive vesicles (Figure 5) and the senescent phenotype. This
absence of the senescent phenotype in GaMG cells may also
explain the steeper slope of growth curves observed for GaMG
spheroids compared to U87 spheroids.
DISCUSSION
In the present work, the activity of temozolomide on glioblastoma
cells grown in multicellular spheroids was investigated. To some
extent, the three-dimensional spheroidal cell culture mimics the in
vivo situation more closely than two-dimensional culture systems
and is suitable for in vitro testing of cytotoxic substances (Terzis
et al, 1997, 1998). Cells inside a spheroid are facing respiratory
stress, lack of nutrients and lack of growth factors. Reports
describing an attenuated response of glioblastoma cells to
temozolomide treatment (Sankar et al, 1999; Hirose et al, 2001)
and a resistance of those cells to undergo apoptosis (Hirose et al,
2001) prompted us to investigate the drug’s ability to induce
programmed cell death in this cell culture model. In p53 proficient
lymphoblastoid tumour cells, it has been shown that temozolomide
application (D’Atri et al, 1998) leads to accumulation of p53 and,
further downstream along the apoptotic pathway, to the specific
DNA degradation pattern.
Owing to penetration difficulties of reporter dyes, the in vivo
testing of viability by conventional assays (MTT-assay, Live–dead-
assay (Molecular Probes)) could not be achieved. Therefore, we
had to rely on TUNEL staining of tissue sections to determine the
number of apoptotic cells in the spheroids. We found that
glioblastoma cell line U87MG, which harbours a functional p53
gene (Van Meir et al, 1994), showed a classical apoptosis pattern
already 2 days after the application of the alkylating drug. In our
study, the sensitivity of the U87 cell line towards temozolomide
was higher and the growth rate significantly lower than that of the
GaMG cell line. Untreated control spheroids of GaMG grew
significantly faster than U87 spheroids, an observation that may be
because of a higher sensitivity to environmental stress factors in
U87 cells. An alternative strategy to circumvent apoptosis is the
prolongation of the G2-M arrest and the induction of a senescent
state in tumour cells. This depends on a functional p53 protein, as
has been described in U87 cells (Hirose et al, 2001). In contrast to
their work carried out on cells grown in monolayer, we could show
that this cell line is able to employ both strategies simultaneously.
In U87MG cells, an intensive senescence-associated galactosidase
activity is seen after temozolomide treatment, an observation we
never made in GaMG cells. Hirose et al (2001) attributed this
accumulation of lysosomal acid b-D-galactosidase (Kurz et al,
2000) to the prolonged G2-M arrest as a consequence of p53
accumulation. In contrast to our data, they could not show an
activation of the apoptosis machinery in U87 cells. This difference
could be explained by the fact that cells in the three-dimensional
framework of a multicellular spheroid are exposed to several stress
factors simultaneously. Moreover, these multiple stress factors can
be integrated on the protein levels by the enzyme poly(ADP-
ribose) polymerase (PARP). For a review see Tong et al (2001).
This enzyme was demonstrated to be highly activated by both
oxidative stress and chemotherapy treatment. It is thought that
1.6 
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kb 
1.0 
0 5  20  0 5  20  0 5  20  0 5  20   g ml-1 temozolomide 
U87 MG  U87 MG  Ga MG  Ga MG 
2 days  7 days 
Figure 4 DNA fragmentation. Laddering phenomenon of fragmented
DNA resolved on a 1.5% agarose gel. Alkylation of DNA by temozolomide
results in induction of apoptosis in U87 cells during the first 48h
postexposure. After 7 days, untreated U87 cells also undergo apoptosis
because of unfavourable culture conditions. GaMG is not initiating
apoptosis after 2 days and a slight induction is observed after 7 days in
culture.
0 g ml-1  20 g ml-1   
U87MG 
GaMG 
Figure 5 Senescence-associated galactosidase activity in glioma
spheroids treated with temozolomide. X-Gal staining revealed that GaMG
spheroids never accumulate a detectable galactosidase activity as a
response to temozolomide treatment. However, U87 cells clearly exhibit
a drug-dependent stimulation of galactosidase activity. This accumulation of
lysosomal galactosidase enzyme is already observed shortly after drug
application.
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sthis protein plays a multifunctional role in many cellular
processes, including DNA repair, recombination, cell proliferation
and death, as well as genomic stability. In collaboration with p53,
PARP is a powerful activator of apoptosis. Active PARP can poly-
ADP-ribosylate the histone H1 and thereby facilitate DNA
fragmentation (Yoon et al, 1996). Inhibition of PARP on the other
hand increases cellular susceptibility to alkylating agents by
inhibiting DNA repair at the G1 checkpoint (Tentori et al, 1998,
2001).
A significant increase of temozolomide toxicity by coapplication
of the MGMT inhibitor O
6-benzylguanine was not seen in the two
cell lines studied. This may be because of the intrinsic MGMT
inactivation by temozolomide alone, which is not the case with
other alkylating agents such as nitrosoureas (Kokkinakis et al,
2001). Alternatively, this can also be explained by low levels of
MGMT protein in glioblastoma cells as a consequence of promoter
silencing observed in glioblastoma cells (Esteller et al, 2000).
In clinical application, temozolomide is given over 5 consecutive
days within an interval of 4 weeks. In our experiments, double
treatment of glioblastoma spheroids with temozolomide with an
intermittent recovery phase of 2 weeks resulted in the complete
destruction of U87 spheroids after the second application of the
drug, while GaMG cultures continued to grow and attained a fairly
high resistance against the drug, albeit under a strong reduction of
growth. This corroborates a recently published clinical study that
showed that ‘long term’ low-dose temozolomide treatment is
ineffective in glioblastoma patients (Khan et al, 2002).
The spheroid model furthermore allows analysing the potential
of the drug to influence one of the most dangerous properties of
glioblastoma cells, the invasion of neighbouring brain tissue
(Terzis et al, 1997, 1998). In a confrontation study, we could show
that temozolomide is able to reduce the invasiveness of
glioblastoma cells into foetal brain aggregates. This is due
presumably to the reduction of cell number and not by reducing
the motility of the glioma cells, as this cellular property remained
unaffected by the alkylating substance. Although the putative
harmful effect of temozolomide on brain aggregates was not
assessed in detail in our study, we did not observe microscopical
alterations like, for example, necrosis or disintegration. In the light
of the slow volume growth during the 3-week maturation process,
we can assume that only few cell divisions occur in the brain
aggregates and most cells are arrested in G0. This stage of the cell
cycle would render the cells relatively resistant to the cytotoxic
effects of temozolomide.
Temozolomide is a potent inhibitor of glioma cell growth. Cells
with a known functional p53 gene and a deficient MGMT
detoxification system undergo either apoptosis or remain in a
senescent state. Both pathways are able to reduce cellular
proliferation and glioblastoma spheroid growth.
The glioblastoma cell line GaMG did not show a significant
apoptotic induction and no senescence-associated galactosidase
accumulation. Despite the evident lack of MGMT expression in
GaMG cells, repetitive sublethal treatment with temozolomide
selects extremely resistant cells.
Taken together, our study suggests that it might be important in
the treatment of glioblastoma to apply temozolomide at the
maximal dosage tolerated in the first cycle in order to avoid
selection of resistant cells.
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